256 related articles for article (PubMed ID: 25990505)
1. CMTM3 is reduced in prostate cancer and inhibits migration, invasion and growth of LNCaP cells.
Hu F; Yuan W; Wang X; Sheng Z; Yuan Y; Qin C; He C; Xu T
Clin Transl Oncol; 2015 Aug; 17(8):632-9. PubMed ID: 25990505
[TBL] [Abstract][Full Text] [Related]
2. CMTM3 inhibits cell growth and migration and predicts favorable survival in oral squamous cell carcinoma.
Zhang H; Zhang J; Nan X; Li X; Qu J; Hong Y; Sun L; Chen Y; Li T
Tumour Biol; 2015 Sep; 36(10):7849-58. PubMed ID: 25946973
[TBL] [Abstract][Full Text] [Related]
3. CMTM5 is reduced in prostate cancer and inhibits cancer cell growth in vitro and in vivo.
Xiao Y; Yuan Y; Zhang Y; Li J; Liu Z; Zhang X; Sheng Z; Xu T; Wang X
Clin Transl Oncol; 2015 Jun; 17(6):431-7. PubMed ID: 25387568
[TBL] [Abstract][Full Text] [Related]
4. miR-135b-5p promotes gastric cancer progression by targeting CMTM3.
Lu M; Huang Y; Sun W; Li P; Li L; Li L
Int J Oncol; 2018 Feb; 52(2):589-598. PubMed ID: 29345297
[TBL] [Abstract][Full Text] [Related]
5. CMTM3 is frequently reduced in clear cell renal cell carcinoma and exhibits tumor suppressor activities.
Xie J; Yuan Y; Liu Z; Xiao Y; Zhang X; Qin C; Sheng Z; Xu T; Wang X
Clin Transl Oncol; 2014 Apr; 16(4):402-9. PubMed ID: 23907292
[TBL] [Abstract][Full Text] [Related]
6. [Knockdown of CMTM3 promotes migration and invasion of PC3 cell in vitro].
Hu FZ; Yuan WQ; Wang XL; Qin CP; Sheng ZZ; DU YQ; Yin HQ; Xu T
Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Aug; 48(4):594-597. PubMed ID: 29263495
[TBL] [Abstract][Full Text] [Related]
7. SMC1A promotes growth and migration of prostate cancer in vitro and in vivo.
Pan XW; Gan SS; Ye JQ; Fan YH; Hong Υ; Chu CM; Gao Y; Li L; Liu X; Chen L; Huang Y; Xu H; Ren JZ; Yin L; Qu FJ; Huang H; Cui XG; Xu DF
Int J Oncol; 2016 Nov; 49(5):1963-1972. PubMed ID: 27667360
[TBL] [Abstract][Full Text] [Related]
8. CMTM3 inhibits human testicular cancer cell growth through inducing cell-cycle arrest and apoptosis.
Li Z; Xie J; Wu J; Li W; Nie L; Sun X; Tang A; Li X; Liu R; Mei H; Wang F; Wang Z; Gui Y; Cai Z
PLoS One; 2014; 9(2):e88965. PubMed ID: 24586462
[TBL] [Abstract][Full Text] [Related]
9. CMTM3 inhibits cell migration and invasion and correlates with favorable prognosis in gastric cancer.
Su Y; Lin Y; Zhang L; Liu B; Yuan W; Mo X; Wang X; Li H; Xing X; Cheng X; Dong B; Hu Y; Du H; Zhu Y; Ding N; Li J; Liu W; Ma Y; Qiu X; Ji J; Han W
Cancer Sci; 2014 Jan; 105(1):26-34. PubMed ID: 24131472
[TBL] [Abstract][Full Text] [Related]
10. Oleanolic acid inhibits cell survival and proliferation of prostate cancer cells in vitro and in vivo through the PI3K/Akt pathway.
Li X; Song Y; Zhang P; Zhu H; Chen L; Xiao Y; Xing Y
Tumour Biol; 2016 Jun; 37(6):7599-613. PubMed ID: 26687646
[TBL] [Abstract][Full Text] [Related]
11. ING3 is associated with increased cell invasion and lethal outcome in ERG-negative prostate cancer patients.
Almami A; Hegazy SA; Nabbi A; Alshalalfa M; Salman A; Abou-Ouf H; Riabowol K; Bismar TA
Tumour Biol; 2016 Jul; 37(7):9731-8. PubMed ID: 26803516
[TBL] [Abstract][Full Text] [Related]
12. CMTM5 inhibits the development of prostate cancer via the EGFR/PI3K/AKT signaling pathway.
Li L; Hu Y; Chen D; Zhu J; Bao W; Xu X; Chen H; Chen W; Feng R
Mol Med Rep; 2022 Jan; 25(1):. PubMed ID: 34791506
[TBL] [Abstract][Full Text] [Related]
13. CKLF-Like MARVEL Transmembrane Domain-Containing Member 3 (CMTM3) Inhibits the Proliferation and Tumorigenisis in Hepatocellular Carcinoma Cells.
Li W; Zhang S
Oncol Res; 2017 Jan; 25(2):285-293. PubMed ID: 27629543
[TBL] [Abstract][Full Text] [Related]
14. A novel 3p22.3 gene CMTM7 represses oncogenic EGFR signaling and inhibits cancer cell growth.
Li H; Li J; Su Y; Fan Y; Guo X; Li L; Su X; Rong R; Ying J; Mo X; Liu K; Zhang Z; Yang F; Jiang G; Wang J; Zhang Y; Ma D; Tao Q; Han W
Oncogene; 2014 Jun; 33(24):3109-18. PubMed ID: 23893243
[TBL] [Abstract][Full Text] [Related]
15. CMTM3 decreases EGFR expression and EGF-mediated tumorigenicity by promoting Rab5 activity in gastric cancer.
Yuan W; Liu B; Wang X; Li T; Xue H; Mo X; Yang S; Ding S; Han W
Cancer Lett; 2017 Feb; 386():77-86. PubMed ID: 27867015
[TBL] [Abstract][Full Text] [Related]
16. CMTM3 (CKLF-Like Marvel Transmembrane Domain 3) Mediates Angiogenesis by Regulating Cell Surface Availability of VE-Cadherin in Endothelial Adherens Junctions.
Chrifi I; Louzao-Martinez L; Brandt M; van Dijk CGM; Burgisser P; Zhu C; Kros JM; Duncker DJ; Cheng C
Arterioscler Thromb Vasc Biol; 2017 Jun; 37(6):1098-1114. PubMed ID: 28428220
[TBL] [Abstract][Full Text] [Related]
17. Klf4 transcription factor is expressed in the cytoplasm of prostate cancer cells.
Le Magnen C; Bubendorf L; Ruiz C; Zlobec I; Bachmann A; Heberer M; Spagnoli GC; Wyler S; Mengus C
Eur J Cancer; 2013 Mar; 49(4):955-63. PubMed ID: 23089465
[TBL] [Abstract][Full Text] [Related]
18. Research Advances in CKLFSF-like MARVEL Transmembrane Domain Containing Member 3.
Hu FZ; Sheng ZZ; Qin CP; Xu T
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2016 Jun; 38(3):360-3. PubMed ID: 27469927
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor as a regulator of ZEB2 expression and its implications in epithelial-to-mesenchymal transition in prostate cancer.
Jacob S; Nayak S; Fernandes G; Barai RS; Menon S; Chaudhari UK; Kholkute SD; Sachdeva G
Endocr Relat Cancer; 2014 Jun; 21(3):473-86. PubMed ID: 24812058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
